Document 0699
 DOCN  M9490699
 TI    Double-blind, randomized clinical trial on the effect of interferon-beta
       in the treatment of condylomata acuminata.
 DT    9411
 AU    Olmos L; Vilata J; Rodriguez Pichardo A; Lloret A; Ojeda A; Calderon MD;
       Department of Dermatology, Hospital Clinico Universitario San; Carlos,
       Madrid, Spain.
 SO    Int J STD AIDS. 1994 May-Jun;5(3):182-5. Unique Identifier : AIDSLINE
       MED/94339220
 AB    A randomized, double-blind, placebo-controlled trial was conducted to
       assess interferon-beta efficacy and safety in the treatment of
       anogenital condylomatous lesions. One hundred patients received a daily
       intramuscular injection of either interferon-beta (IFN-beta) (2 MIU/day)
       or placebo for 10 days. Of 94 evaluable patients, the complete response
       rate observed 8 weeks after treatment was significantly higher in the
       group receiving IFN-beta, as compared to the placebo-treated group (51%
       vs 28.9%, P < 0.05). After one year, 24 patients (100%) out of 24
       complete responders to IFN-beta who attended for follow-up remained free
       of lesions. Twelve of 13 patients with complete response to placebo
       (92.3%) remained free of lesions after one year. Side effects were mild
       and no significant analytical changes were observed. In conclusion,
       interferon-beta is an effective and safe treatment for long-term
       eradication of anogenital condylomatous lesions.
 DE    Adult  Condylomata Acuminata/*THERAPY  Double-Blind Method  Female
       Follow-Up Studies  Human  Injections, Intramuscular
       Interferon-beta/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/  *THERAPEUTIC
       USE  Male  Middle Age  Spain  Support, Non-U.S. Gov't  CLINICAL TRIAL
       CLINICAL TRIAL, PHASE III  JOURNAL ARTICLE  MULTICENTER STUDY
       RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).